Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
- Status
- COMPLETED
- Phase
- NA
Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
- Status
- TERMINATED
- Phase
- NA
Randomized Trial for Mixed Acute Rejection
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Romidepsin and Bortezomib for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- Status
- WITHDRAWN
- Phase
- PHASE2
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
- Status
- COMPLETED
- Phase
- PHASE2
Natural Killer Cells and Bortezomib to Treat Cancer
- Status
- COMPLETED
- Phase
- PHASE1